Concepedia

Author

Qing Chang

Memorial Sloan Kettering Cancer CenterORCID

Also Known As

Chang Qing, Q Chang, Qing CHANG, Qing Chang

107

Publications

1.6K

Citations

16

H-Index

25

Concepts

All Affiliations

Memorial Sloan Kettering Cancer CenterCornell UniversityNew York UniversityWeill Cornell MedicineUniversity of California, San Francisco
QC

About

Qing Chang is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, pharmacology, and inflammatory lung disease.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

219

2

Pharmacology

2

2

185

3

Natural Sciences

1

1

34

4

Cell Biology

1

1

34

5

Pathology

1

1

54

Qing Chang

×

17

Publications

1.5K

Citations

15

H-Index

YearCitations

Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer

Pasquale Sansone, Claudia Savini, Ivana Kurelac,

Proceedings of the National Academy of Sciences

2017

698

Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis

Libo Zhao, Xiaomin Wang, Qing Chang,

European Journal of Pharmacology

2009

131

Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Rona Yaeger, Riccardo Mezzadra, Jenna Sinopoli,

Cancer Discovery

2022

122

Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

Yuting Sun, Brooke A. Meyers, Barbara Czakó,

Cancer Research

2020

101

Cooperative CAR targeting to selectively eliminate AML and minimize escape

Sascha Haubner, Jorge Mansilla‐Soto, Sarah Nataraj,

Cancer Cell

2023

93

JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors

Sizhi Paul Gao, Qing Chang, Ninghui Mao,

Science Signaling

2016

63

A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib

Helena A. Yu, Leslie Perez, Qing Chang,

Journal of Thoracic Oncology

2016

54

Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers

Walid K. Chatila, Henry Walch, Jaclyn F. Hechtman,

Nature Communications

2023

45

Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis

Shanshan Duan, Loredana Moro, Rui Qu,

Cell Reports

2021

35

Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules

Kamini Singh, Jianan Lin, Nicolas Lecomte,

Cancer Research

2021

34

Page 1